Efficient Growth Inhibition of ErbB2-overexpressing Tumor Cells by Antierbb2 ScFv-Fc-IL-2 Fusion Protein in Vitro and in Vivo

Ming Shi,Ling Zhang,Hong-tao Gu,Feng-qin Jiang,Lu Qian,Ming Yu,Guo-jiang Chen,Qun Luo,Bei-fen Shen,Ning Guo
DOI: https://doi.org/10.1111/j.1745-7254.2007.00622.x
2007-01-01
Abstract:Aim:To investigate the antitumor activities of an anti-ErbB2 scFv-Fc-interleukin2 (IL-2) fusion protein (HFI) in vitro and in vivo.Methods:Fusion protein HFI wasconstructed.The efficacy of HFI in mediating tumor cell lysis was determined bycolorimetric lactate dehydrogenase release assays.The antitumor activity of HFIwas evaluated in tumor xenograft models.Results:The fusion protein was foldedas a homodimer formed by covalently linking Fc portions and it retained ErbB2specificity and IL-2 biological activity.HFI mediated antibody-dependent cell-mediated cytotoxicity (ADCC) at low effector-to-target ratios in vitro and im-proved the therapeutic efficacy of IL-2 in experiments in vivo.Conclusion:Thegenetically-engineered anti-ErbB2 scFv-Fc-IL-2 fusion protein exhibited high ef-ficiency both in mediating ADCC in vitro and significant antitumor activity intumor xenograft models.
What problem does this paper attempt to address?